GHK-Cu

GHK-Cu is a naturally occurring copper-binding tripeptide that stimulates collagen synthesis and shifts gene expression toward a younger phenotype. It is widely used as a topical cosmetic ingredient and research injectable, and is not FDA-regulated as a drug when sold for cosmetic use.

GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, a naturally occurring tripeptide present in human plasma, saliva, and urine. The peptide was first identified in the early 1970s by Loren Pickart, who was investigating why serum from young donors caused aged human liver tissue to behave more like young tissue in culture. The active fraction was purified and its structure reported as glycyl-histidyl-lysine by Schlesinger, Pickart, and Thaler in Experientia in 1977. Its defining chemical property is a very high affinity for copper(II): the histidine imidazole nitrogen, the terminal amine, and the peptide backbone nitrogen form a square-planar chelate that was characterized in solution by Freedman and colleagues in Biochemistry in 1982. This chelate is stable enough to hold copper in circulation but exchangeable enough to hand it off to copper-dependent enzymes at tissue sites, which is why GHK is generally described as a copper carrier rather than simply a copper salt. Plasma GHK is reported at roughly 200 ng/mL at age 20, declining to roughly 80 ng/mL by age 60 — an age-related decline that motivates most of the anti-aging interest in the molecule.

GHK-Cu occupies two very different commercial positions, and conflating them is the single most common source of confusion about it. As a topical cosmetic ingredient it is mainstream, decades-old, and sold without restriction: copper peptide serums and creams typically list GHK-Cu (INCI: copper tripeptide-1) at concentrations in the low single-digit percent range, and this is where nearly all human exposure data comes from. As an injectable research peptide it is an entirely different proposition — the systemic pharmacology, dose-response, and copper-loading consequences of subcutaneous GHK-Cu in humans have not been characterized in any published clinical trial. The evidence base does not transfer between these two routes, and readers evaluating injectable protocols should treat the topical cosmetic literature as inapplicable.

The research literature clusters into four domains. The oldest and best-supported is dermal extracellular matrix biology: GHK-Cu stimulates collagen, elastin, glycosaminoglycan, and proteoglycan synthesis in cultured fibroblasts, and simultaneously increases matrix metalloproteinase-2 alongside its tissue inhibitors TIMP-1 and TIMP-2 — a combination consistent with active remodeling rather than simple deposition. The second is wound healing, studied largely in rodent and in vitro models. The third, and the source of much of the modern interest, is gene expression: analysis through the Broad Institute Connectivity Map identified GHK as a compound capable of reversing disease-associated transcriptional signatures, a finding first published for emphysematous lung tissue by Campbell and colleagues in Genome Medicine in 2012. The fourth is a more recent Chinese-led body of work on GHK-Cu in pulmonary and skeletal-muscle pathology, mostly via SIRT1 and oxidative-stress pathways in mice.

GHK-Cu's US regulatory position changed materially in the 2020s. It was among the substances the FDA placed in Category 2 in 2023, ending legal compounding-pharmacy preparation, and it is one of 12 peptides covered by the FDA's April 15, 2026 action removing them from that list after the original nominators withdrew their nominations — an action that did not place any of them on the 503A Bulks List and did not restore compounding eligibility. It was not among the seven peptides taken up at the Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026; instead the FDA has said the committee will reconvene before the end of February 2027 to consider GHK-Cu together with LL-37, dihexa acetate, Melanotan II, and pegylated mechano growth factor. None of this affects topical cosmetic sale, which is regulated under cosmetic rather than drug authority and has continued uninterrupted throughout.

GHK-Cu's primary mechanism is copper delivery. Copper is a required cofactor for lysyl oxidase (which cross-links collagen and elastin fibers), superoxide dismutase 1 (a principal cytosolic antioxidant enzyme), tyrosinase, and cytochrome c oxidase. Free copper ions are toxic and pro-oxidant, so the body moves copper almost entirely bound to carriers; GHK's chelate geometry — characterized by Freedman and colleagues in 1982 — makes it an effective physiological shuttle that can release copper to higher-affinity acceptor proteins at target tissues. This distinction matters experimentally. Siméon and colleagues (Life Sciences, 2000) found that GHK-Cu's stimulation of MMP-2 in dermal fibroblasts was reproduced by copper ions alone but not by the uncomplexed GHK tripeptide, indicating that for that particular effect the copper, not the peptide, is the active moiety. Other effects behave in the opposite direction, and the field has not fully resolved which actions require the intact complex.

In the dermal extracellular matrix, GHK-Cu acts on fibroblasts to increase synthesis of type I collagen (Maquart and colleagues, FEBS Letters, 1988), sulfated glycosaminoglycans including dermatan sulfate and chondroitin sulfate (Wegrowski and colleagues, Life Sciences, 1992), and the small proteoglycans decorin and biglycan in healing wounds (Siméon and colleagues, Journal of Investigative Dermatology, 2000). Because it concurrently raises MMP-2 and its TIMP inhibitors, the net effect described in the literature is coordinated matrix turnover — degradation of damaged matrix paired with deposition of new — rather than unopposed accumulation, which is the pattern associated with fibrosis. In keratinocytes, copper-GHK increases integrin expression and the proportion of p63-positive cells (Kang and colleagues, Archives of Dermatological Research, 2009), markers associated with basal-layer proliferative capacity and epidermal renewal.

The widely repeated claim that GHK modulates roughly 4,000 human genes traces to Pickart and Margolina's 2018 analysis of Broad Institute Connectivity Map data, in which GHK exposure was associated with up- or downregulation of that order of magnitude of transcripts, including a set of DNA-repair genes. This is transcriptomic screening data from cell lines, not a demonstration of clinical effect, and the number describes breadth of transcriptional response rather than therapeutic benefit. The mechanistically more concrete version of the same finding is Campbell and colleagues' 2012 work, which used the Connectivity Map to search for compounds that reverse a 127-gene signature of emphysematous lung destruction, identified GHK, and then showed in cultured COPD-derived fibroblasts that GHK restored collagen gel contraction and organization in a manner resembling TGF-beta pathway activation.

A newer mechanistic thread concerns SIRT1 and oxidative stress outside the skin. GHK-Cu reduced cigarette-smoke-induced pulmonary emphysema and inflammation through oxidative-stress pathways in mice (Zhang and colleagues, Frontiers in Molecular Biosciences, 2022), relieved airway remodeling via SIRT1 activation in airway epithelial cells (Zhang and colleagues, Biomedicine and Pharmacotherapy, 2023), rescued smoking-induced skeletal muscle dysfunction through a SIRT1-dependent pathway (Deng and colleagues, Journal of Cachexia, Sarcopenia and Muscle, 2023), and attenuated silicosis-related lung inflammation and fibrosis by targeting peroxiredoxin 6 (Bian and colleagues, Redox Biology, 2024). These are systemic-administration rodent studies and are the closest existing analogue to injectable human use, though they were conducted in disease models rather than healthy animals.

The GHK-Cu evidence base is unusually lopsided: strong and long-running in cell culture, moderate in animal models, and thin in controlled human trials despite fifty years of study and widespread cosmetic use.

The fibroblast and matrix literature is the most solid component. Maquart and colleagues (FEBS Letters, 1988) demonstrated stimulation of collagen synthesis in fibroblast cultures by GHK-Cu at nanomolar concentrations. Wegrowski and colleagues (Life Sciences, 1992) showed increased sulfated glycosaminoglycan synthesis. Siméon and colleagues published two distinct 2000 papers that are frequently confused with each other: one in the Journal of Investigative Dermatology on glycosaminoglycan and small-proteoglycan expression in wounds, and one in Life Sciences showing GHK-Cu increases MMP-2 along with TIMP-1 and TIMP-2 in dermal fibroblasts. Kang and colleagues (Archives of Dermatological Research, 2009) extended the work to keratinocytes. These are consistent, independently replicated in vitro findings from established matrix-biology groups.

Human skin evidence is where the literature is weakest relative to its reputation. The most-cited human result — a 12-week facial cream trial in 71 women with photoaged skin reporting improved skin density, thickness, and wrinkle depth — was presented by Leyden and colleagues as a 2002 American Academy of Dermatology meeting abstract and is known almost entirely through secondary description in Pickart's reviews; it was not published as a peer-reviewed full paper, so its methods cannot be independently assessed. A widely circulated 'GHK-Cu increases collagen 70%' claim appears to originate in a misreading of one of these reviews, which reports that collagen increases were observed in 70 percent of the women treated with GHK-Cu, compared with 50 percent for a vitamin C cream and 40 percent for retinoic acid. That is a responder rate, not an effect size, and PeptaHub previously repeated the incorrect version. No large, registered, peer-reviewed randomized controlled trial of topical GHK-Cu has been published.

Wound healing evidence is animal and in vitro. Wang and colleagues (Wound Repair and Regeneration, 2017) reported that GHK-Cu delivered in liposomes accelerated scald wound healing in mice through increased cell proliferation and angiogenesis. Hair-related evidence is thinner than commonly claimed: Uno and Kurata's 1993 Journal of Investigative Dermatology work on chemical agents and peptides affecting hair growth is the usual primary citation, while the frequently cited Pyo and colleagues 2007 study in Archives of Pharmacal Research tested AHK-Cu — a different alanyl tripeptide-copper complex — and does not constitute GHK-Cu evidence. There are no published randomized controlled trials of GHK-Cu for hair loss.

The gene-expression and systemic-disease work represents the most active current research front. Campbell and colleagues (Genome Medicine, 2012) derived a 127-gene signature of emphysema severity from 64 lung tissue samples, used the Connectivity Map to identify GHK as a signature-reversing compound, and validated a functional effect on COPD-derived fibroblast collagen remodeling — a genuinely hypothesis-generating result that prompted a companion commentary in the same journal. Since 2022, several Chinese groups have reported systemic GHK-Cu effects in rodent models of smoke-induced emphysema, ovalbumin-induced airway remodeling, silicosis, colitis, and smoking-related skeletal muscle dysfunction, converging on SIRT1 and redox pathways. None of this work has advanced to human trials.

The practical bottom line is a split verdict by route. Topical GHK-Cu has a plausible mechanism, an extensive supporting in vitro literature, decades of consumer use with a benign reported safety profile, and weak controlled human efficacy data. Injectable GHK-Cu has no published human pharmacokinetic, dose-finding, or safety data at all, and the systemic copper-loading question — relevant given copper's narrow therapeutic window and the existence of genuine copper-overload disease — has not been addressed in any clinical study.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]

Peptides commonly paired with GHK-Cu for synergistic effects.